Amgen Reports Third Quarter 2017 Financial Results
THOUSAND OAKS, Calif., Oct. 25, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2017. Key results include:
Total revenues decreased 1 percent versus the third quarter of 2016 to $5.8 billion.
GAAP earnings per share (EPS) increased 3 percent to $2.76.
GAAP operating income decreased 3 percent to $2.4 billion and GAAP operating margin decreased 1.1 percentage points to 44.7 percent.
GAAP EPS and operating income were impacted by non-cash charges associated with the Company's decision to discontinue internal development of AMG 899, an oral CETP inh...
Source: Amgen News Release - October 25, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces Appointment Of Wanda M. Austin To Board Of Directors
THOUSAND OAKS, Calif., Oct. 24, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the appointment of Wanda M. Austin to its Board of Directors, effective upon the December Board and committee meetings. Dr. Austin will serve as a member of the Board's Audit Committee and the Corporate Responsibility and Compliance Committee. Following the appointment of Dr. Austin, the Board will comprise 14 directors, 13 of whom are independent.
"We are pleased to welcome Dr. Wanda Austin to Amgen's Board," said Robert A. Bradway, chairman and chief executive officer of Amgen. "Wanda's deep experience in long-cycle technology...
Source: Amgen News Release - October 24, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces 2017 Fourth Quarter Dividend
THOUSAND OAKS, Calif., Oct. 24, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $1.15 per share dividend for the fourth quarter of 2017. The dividend will be paid on Dec. 8, 2017, to all stockholders of record as of the close of business on Nov. 17, 2017.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understan...
Source: Amgen News Release - October 24, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Award-Winning Journalist And Cancer Survivor Joan Lunden Partners With Amgen To Launch 'At Home With Joan' To Empower Patients Battling Cancer
Unique Campaign Highlights the Importance of Understanding Your Treatment and Building a Support Community, With Advice From Joan Lunden, Cancer Survivors and Healthcare Professionals
Campaign Encourages Patients to Advocate for Themselves When Facing Strong Chemotherapy and Associated Risks
THOUSAND OAKS, Calif., Oct. 24, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of At Home with Joan, a campaign led by breast cancer survivor and advocate Joan Lunden. This campaign aims to empower patients diagnosed with cancer to be active participants in their treatment plan in order to understand and na...
Source: Amgen News Release - October 24, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Phase 3 A.R.R.O.W. Study Of Once-Weekly KYPROLIS ® (Carfilzomib) Regimen Meets Primary Endpoint Of Progression-Free Survival In Relapsed And Refractory Multiple Myeloma Patients
Once-Weekly KYPROLIS at 70 mg/m2 Shows Superior Efficacy and Comparable Safety to Twice-Weekly KYPROLIS at 27 mg/m2
Positive Results From Pre-Specified Interim Analysis
THOUSAND OAKS, Calif., Oct. 23, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced top-line results of the Phase 3 A.R.R.O.W. trial, which showed KYPROLIS® (carfilzomib) administered once-weekly at the 70 mg/m2 dose with dexamethasone allowed relapsed and refractory multiple myeloma patients to live 3.6 months longer without their disease worsening than KYPROLIS administered twice-weekly at the 27 mg/m2 dose with dexamethasone. The overall s...
Source: Amgen News Release - October 23, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces Webcast of 2017 Third Quarter Financial Results
THOUSAND OAKS, Calif., Oct. 20, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Wednesday, Oct. 25, 2017, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and ...
Source: Amgen News Release - October 20, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And Boston Children's Hospital Enter A Collaboration To Find New Genes And Drug Targets For Severe Pain Syndromes
CAMBRIDGE, Mass., Oct. 16, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Boston Children's Hospital today announced that they have entered into a neuroscience research collaboration aimed at identifying novel pain targets based on human genetic analyses. The one-year collaboration will focus on patients with genetic anomalies of pain sensitivity. Amgen will leverage its industry-leading expertise in genetic target identification and validation and will have access to Boston Children's Hospital's Division of Pain Medicine to identify patients with abnormal pain conditions. Amgen and Boston Children's Hospital will collaborat...
Source: Amgen News Release - October 16, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Foundation Awards Khan Academy $3 Million To Support Development Of Free Comprehensive Biology Lessons
More Than One Million Students Access Biology Content Each Month
THOUSAND OAKS, Calif. and MOUNTAIN VIEW, Calif., Oct. 12, 2017 /PRNewswire/ -- The Amgen Foundation today announced a three-year, $3 million grant to Khan Academy to develop comprehensive new biology lessons. The Amgen Foundation is the exclusive sponsor of Khan Academy's biology content.
With the Amgen Foundation's support, Khan Academy will create new biology lessons for students and teachers worldwide. New videos, articles and practice exercises for ninth-grade biology through Advanced Placement Program® (A...
Source: Amgen News Release - October 12, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
FDA Accepts Supplemental Biologics License Application For Prolia ® (Denosumab) In Glucocorticoid-Induced Osteoporosis
Glucocorticoid-Induced Osteoporosis is the Most Common Form of Secondary Osteoporosis
THOUSAND OAKS, Calif., Oct. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Prolia® (denosumab) for the treatment of patients with glucocorticoid-induced osteoporosis (GIOP). The sBLA, which was submitted on July 28, 2017, is based on a Phase 3 study evaluating Prolia compared with risedronate in patients receiving glucocorticoid treatment. The FDA has set a Prescription Drug User Fee Act (PD...
Source: Amgen News Release - October 9, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And LabCentral Open Nomination Process For Lab Residency
Opportunity for Life Sciences and Biotech Startups to Submit Proposal to Win Golden Ticket
CAMBRIDGE, Mass., Oct. 6, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and LabCentral today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden Ticket is open for interested life sciences and biotech startup companies. LabCentral is an innovative, shared laboratory space designed as a launchpad for premier high-impact life sciences and biotech startups. As one of LabCentral's platinum sponsors, Amgen can nominate up to two early-stage companies each year to take up residence in ...
Source: Amgen News Release - October 6, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
